Indivi is an ISO 13485 and ISO 27001-certified TechBio company headquartered in Basel, Switzerland that creates precision-medicine software and sensor-based tools to generate functional and electrophysiological biomarkers for neurological disorders. Its platform combines multimodal deep phenotyping—merging biological electrophysiology data with sensor-derived cognitive and motor assessments—to deliver clearer Proof-of-Biology and Proof-of-Concept signals in clinical trials. The technology is aimed at de-risking early clinical development for indications such as multiple sclerosis, Parkinson’s disease, Alzheimer’s disease, muscular dystrophies and other neuromuscular disorders by improving the signal-to-noise ratio of trial endpoints. Indivi recently partnered with Clouds of Care to unify R&D efforts around this multimodal approach. With fresh financing, the company plans to launch a proof-of-concept trial in 2026 that will seek new functional and electrophysiological biomarkers responsive to β-amyloid-depleting therapies in Alzheimer’s disease. Successful validation could increase the likelihood of detecting treatment efficacy earlier and accelerate time-to-market for biopharma partners. The latest CHF15 million raise expands Indivi’s resources to validate and deploy its biomarker platform across neuroscience drug development.

Total raised

$19M

Funding rounds

1

Latest round

Equity

Latest activity

Nov 2025